{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T12:31:35Z","timestamp":1764937895165,"version":"3.44.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T00:00:00Z","timestamp":1753142400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T00:00:00Z","timestamp":1753142400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s12325-025-03305-5","type":"journal-article","created":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T08:33:27Z","timestamp":1753173207000},"page":"4706-4716","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Ixekizumab Improves Signs, Symptoms, and Quality of Life in Patients with Axial Spondyloarthritis Irrespective of Symptom Duration"],"prefix":"10.1007","volume":"42","clinical-trial-number":[{"clinical-trial-number":"nct02696785","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02696798","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02757352","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4527-852X","authenticated-orcid":false,"given":"Victoria","family":"Navarro-Comp\u00e1n","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John D.","family":"Reveille","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Proton","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 A.","family":"Maldonado-Cocco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Magrey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Bolce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tommaso","family":"Panni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andris","family":"Kronbergs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Rudwaleit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,22]]},"reference":[{"issue":"10089","key":"3305_CR1","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S0140-6736(16)31591-4","volume":"390","author":"J Sieper","year":"2017","unstructured":"Sieper J, Poddubnyy D. Axial spondyloarthritis. Lancet. 2017;390(10089):73\u201384.","journal-title":"Lancet"},{"issue":"6","key":"3305_CR2","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1136\/annrheumdis-2012-201766","volume":"72","author":"J Sieper","year":"2013","unstructured":"Sieper J, van der Heijde D, Dougados M, et al. Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1). Ann Rheum Dis. 2013;72(6):815\u201322.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"3305_CR3","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.3899\/jrheum.141278","volume":"42","author":"X Baraliakos","year":"2015","unstructured":"Baraliakos X, Koenig AS, Jones H, Szumski A, Collier D, Bananis E. Predictors of clinical remission under anti-tumor necrosis factor treatment in patients with ankylosing spondylitis: pooled analysis from large randomized clinical trials. J Rheumatol. 2015;42(8):1418\u201326.","journal-title":"J Rheumatol"},{"issue":"6","key":"3305_CR4","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1136\/ard.2003.016386","volume":"63","author":"M Rudwaleit","year":"2004","unstructured":"Rudwaleit M, Listing J, Brandt J, Braun J, Sieper J. Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis. Ann Rheum Dis. 2004;63(6):665\u201370.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"3305_CR5","doi-asserted-by":"publisher","first-page":"801","DOI":"10.3899\/jrheum.081048","volume":"36","author":"M Rudwaleit","year":"2009","unstructured":"Rudwaleit M, Claudepierre P, Wordsworth P, et al. Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis. J Rheumatol. 2009;36(4):801\u20138.","journal-title":"J Rheumatol"},{"issue":"10","key":"3305_CR6","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.1002\/art.38070","volume":"65","author":"N Haroon","year":"2013","unstructured":"Haroon N, Inman RD, Learch TJ, et al. The impact of tumor necrosis factor alpha inhibitors on radiographic progression in ankylosing spondylitis. Arthritis Rheum. 2013;65(10):2645\u201354.","journal-title":"Arthritis Rheum"},{"key":"3305_CR7","doi-asserted-by":"publisher","first-page":"39","DOI":"10.2147\/JIR.S100940","volume":"9","author":"L Liu","year":"2016","unstructured":"Liu L, Lu J, Allan BW, et al. Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A. J Inflamm Res. 2016;9:39\u201350.","journal-title":"J Inflamm Res"},{"issue":"2","key":"3305_CR8","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1136\/annrheumdis-2019-216118","volume":"79","author":"M Dougados","year":"2020","unstructured":"Dougados M, Wei JC, Landew\u00e9 R, et al. Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W). Ann Rheum Dis. 2020;79(2):176\u201385.","journal-title":"Ann Rheum Dis"},{"issue":"10217","key":"3305_CR9","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S0140-6736(19)32971-X","volume":"395","author":"A Deodhar","year":"2020","unstructured":"Deodhar A, van der Heijde D, Gensler LS, et al. Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial. Lancet. 2020;395(10217):53\u201364.","journal-title":"Lancet"},{"key":"3305_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2022.152032","volume":"55","author":"D Benavent","year":"2022","unstructured":"Benavent D, Capelusnik D, van der Heijde D, et al. How is early spondyloarthritis defined in the literature? Results from a systematic review. Semin Arthritis Rheum. 2022;55: 152032.","journal-title":"Semin Arthritis Rheum"},{"issue":"10163","key":"3305_CR11","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1016\/S0140-6736(18)31946-9","volume":"392","author":"D van der Heijde","year":"2018","unstructured":"van der Heijde D, Cheng-Chung Wei J, Dougados M, et al. Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial. Lancet. 2018;392(10163):2441\u201351.","journal-title":"Lancet"},{"issue":"4","key":"3305_CR12","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1002\/art.40753","volume":"71","author":"A Deodhar","year":"2019","unstructured":"Deodhar A, Poddubnyy D, Pacheco-Tena C, et al. Efficacy and safety of ixekizumab in the treatment of radiographic axial spondyloarthritis: sixteen-week results from a phase III randomized, double-blind, placebo-controlled trial in patients with prior inadequate response to or intolerance of tumor necrosis factor inhibitors. Arthritis Rheumatol. 2019;71(4):599\u2013611.","journal-title":"Arthritis Rheumatol"},{"issue":"10","key":"3305_CR13","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1136\/ard.2009.110767","volume":"68","author":"M Rudwaleit","year":"2009","unstructured":"Rudwaleit M, Jurik AG, Hermann KG, et al. Defining active sacroiliitis on magnetic resonance imaging (MRI) for classification of axial spondyloarthritis: a consensual approach by the ASAS\/OMERACT MRI group. Ann Rheum Dis. 2009;68(10):1520\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"3305_CR14","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1136\/ard.2009.108233","volume":"68","author":"M Rudwaleit","year":"2009","unstructured":"Rudwaleit M, van der Heijde D, Landew\u00e9 R, et al. The development of assessment of spondyloarthritis international society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009;68(6):777\u201383.","journal-title":"Ann Rheum Dis"},{"key":"3305_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003455","author":"A Ciurea","year":"2023","unstructured":"Ciurea A, Gotschi A, Bram R, et al. Early axial spondyloarthritis according to the ASAS consensus definition: characterisation of patients and effectiveness of a first TNF inhibitor in a large observational registry. RMD Open. 2023. https:\/\/doi.org\/10.1136\/rmdopen-2023-003455.","journal-title":"RMD Open"},{"issue":"9","key":"3305_CR16","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1136\/ard-2023-224232","volume":"83","author":"V Navarro-Comp\u00e1n","year":"2024","unstructured":"Navarro-Comp\u00e1n V, Benavent D, Capelusnik D, et al. ASAS consensus definition of early axial spondyloarthritis. Ann Rheum Dis. 2024;83(9):1093\u20139.","journal-title":"Ann Rheum Dis"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03305-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03305-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03305-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T17:20:22Z","timestamp":1757265622000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03305-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,22]]},"references-count":16,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["3305"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03305-5","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"type":"print","value":"0741-238X"},{"type":"electronic","value":"1865-8652"}],"subject":[],"published":{"date-parts":[[2025,7,22]]},"assertion":[{"value":"5 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Victoria Navarro-Comp\u00e1n has served as a speaker, consultant, and\/or instructor for AbbVie, Alfasigma, Eli Lilly and Company, Fresenius Kabi, Galapagos, Janssen, Novartis, Pfizer, and UCB Pharma, and has received grant and\/or research support from ASAS and Novartis. John D. Reveille has served as a consultant for Eli Lilly and Company and has received grant and\/or research support from Eli Lilly and Company. Proton Rahman has served as a speaker and instructor for Abbott, AbbVie, Amgen, Bristol Myers Squibb, Celgene, Eli Lilly and Company, Janssen, Novartis, Pfizer, and UCB Pharma, and has received grant and\/or research support from Janssen and Novartis. Jos\u00e9 A. Maldonado-Cocco has served as a speaker and consultant for and has received grant and\/or research support from AbbVie, Bristol Myers Squibb, Gilead Sciences, Merck Sharp & Dohme, Novartis, Pfizer, Roche, Sanofi-Aventis, Schering-Plough, UCB Pharma, and Wyeth. Marina Magrey has served as a speaker and\/or consultant for AbbVie, Bristol Myers Squibb, Eli Lilly and Company, Janssen, Novartis, Pfizer, and UCB Pharma. Rebecca Bolce is a former and Tommaso Panni, and Andris Kronbergs are current employees and shareholders of Eli Lilly and Company. Martin Rudwaleit has served as a speaker, consultant, and\/or instructor for AbbVie, Boehringer Ingelheim, Bristol Myers Squibb, Chugai Pharmaceutical, Eli Lilly and Company, Janssen, Novartis, Pfizer, and UCB Pharma.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The trials described herein were conducted in accordance with the ethical principles of the Declaration of Helsinki and were approved by the ethics review boards at each participating study site. The master ethics committee was Schulman Associates IRB, Cincinnati, OH, USA (IRB reference numbers: COAST-V, 201506061; COAST-W, 201506079; COAST-X, 201601302). All patients provided written informed consent prior to participating in the trials.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}